14Feb/13

Empresas.- El tratamiento del linfoma no Hodgkin indolente con bendamustina y … – Europa Press

Monoclonal Anti-CD20 Antibodies

Europa Press

Empresas.- El tratamiento del linfoma no Hodgkin indolente con bendamustina y …
Europa Press
El tratamiento del linfoma no Hodgkin indolente con bendamustina y rituximab es “más eficaz y menos tóxico” que la terapia estándar R-CHOP, tal y como ha asegurado el líder del estudio en Fase III ‘Stil-NHL-01 y miembro de la Universidad de Giessen …
Menos medicamentos, menos toxicidadEl Comercio Digital (Asturias)

all 2 news articles »
14Feb/13

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib – The Pharma Letter

Monoclonal Anti-CD20 Antibodies

US FDA grants “breakthrough” status for Janssen and Pharmacyclics ibrutinib
The Pharma Letter
A Phase III randomized, multi-center registration trial of ibrutinib as a monotherapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen, RAY (MCL3001). • A Phase III …
14Feb/13

Theradiag's new biotherapy monitoring kits receive CE mark approval – News-Medical.net

Monoclonal Anti-CD20 Antibodies

Theradiag’s new biotherapy monitoring kits receive CE mark approval
News-Medical.net
Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for two new biotherapy monitoring kits; Tocilizumab (anti-IL6R) and Rituximab (anti-CD20) that …

and more »
14Feb/13

Antibodies as drugs: Vancouver hosts conference on therapeutic use of antibodies – The Vancouver Observer

Antibodies

Antibodies as drugs: Vancouver hosts conference on therapeutic use of antibodies
The Vancouver Observer
At the front line of these battles, you will find an infantry of antibodies, warriors capable of learning from the enemy and using weapons crafted from antibiotics. As the bacterial enemy’s strength and agility increases, medical science is looking for …